Adaptive Biotechnologies Shares Owned By Institutions vs. EBITDA
| ADPT Stock | USD 6.44 0.05 0.78% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.5563 |
|
|
For Adaptive Biotechnologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Adaptive Biotechnologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Adaptive Biotechnologies Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Adaptive Biotechnologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Adaptive Biotechnologies Corp over time as well as its relative position and ranking within its peers.
Adaptive |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Revenue Per Share 1.211 | Quarterly Revenue Growth 0.225 | Return On Assets (0.16) | Return On Equity (0.67) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Adaptive Biotechnologies EBITDA vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Adaptive Biotechnologies's current stock value. Our valuation model uses many indicators to compare Adaptive Biotechnologies value to that of its competitors to determine the firm's financial worth. Adaptive Biotechnologies Corp is rated third in shares owned by institutions category among its peers. It is rated below average in ebitda category among its peers . At this time, Adaptive Biotechnologies' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adaptive Biotechnologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adaptive EBITDA vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Adaptive Biotechnologies |
| = | 93.92 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Adaptive Biotechnologies |
| = | (189.27 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Adaptive EBITDA Comparison
Adaptive Biotechnologies is currently under evaluation in ebitda category among its peers.
Adaptive Biotechnologies Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Adaptive Biotechnologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Adaptive Biotechnologies will eventually generate negative long term returns. The profitability progress is the general direction of Adaptive Biotechnologies' change in net profit over the period of time. It can combine multiple indicators of Adaptive Biotechnologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 215 K | 225.8 K | |
| Net Interest Income | -853 K | -810.4 K | |
| Interest Income | 13.5 M | 14.2 M | |
| Operating Income | -227 M | -215.7 M | |
| Net Loss | -196 M | -205.8 M | |
| Income Before Tax | -225.3 M | -214 M | |
| Total Other Income Expense Net | 1.7 M | 2.5 M | |
| Net Loss | -180.2 M | -189.2 M | |
| Net Loss | -225.2 M | -214 M | |
| Income Tax Expense | -54 K | -56.7 K | |
| Non Operating Income Net Other | 3.7 M | 3.3 M | |
| Change To Netincome | 64.9 M | 68.2 M | |
| Net Loss | (1.56) | (1.64) | |
| Income Quality | 0.69 | 0.73 | |
| Net Income Per E B T | 1.00 | 0.72 |
Adaptive Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Adaptive Biotechnologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Adaptive Biotechnologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Adaptive Biotechnologies' important profitability drivers and their relationship over time.
Use Adaptive Biotechnologies in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Adaptive Biotechnologies Pair Trading
Adaptive Biotechnologies Corp Pair Trading Analysis
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Adaptive Biotechnologies position
In addition to having Adaptive Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Realty Funds Thematic Idea Now
Realty Funds
Funds or Etfs investing in real estate backed instruments or issues backed by different types of commercial properties. The Realty Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Realty Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.